Focus: Neurology – Hereditary TTR Amyloidosis, Acute Hepatic Porphyria Alnylam is the leading RNAi therapeutics company. We believe our efforts have the potential to improve the lives of Canadian rare disease patients.
Pharmaceutical Companies
.png)
